Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Bikkasani, Krishna
Qin, Qian
Lin, Justin
Galsky, Matt D.
Liaw, Bobby Chi-Hung
Oh, William K.
Tsao, Che-Kai
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA
[2] CUNY, Sch Med, New York, NY 10031 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.184
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
184
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
    Kato, Haruo
    Furuya, Yosuke
    Miyazawa, Yoshiyuki
    Miyao, Takeshi
    Syuto, Takahiro
    Nomura, Masashi
    Sekine, Yoshitaka
    Koike, Hidekazu
    Matsui, Hiroshi
    Shibata, Yasuhiro
    Ito, Kazuto
    Suzuki, Kazuhiro
    ANTICANCER RESEARCH, 2016, 36 (11) : 6141 - 6149
  • [22] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Heidegger, Isabel
    Pircher, Andreas
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09) : 890 - 891
  • [23] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [24] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [25] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
  • [26] Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
    Michael J. Grayling
    Martina McMenamin
    Robert Chandler
    Rakesh Heer
    James M. S. Wason
    BMC Cancer, 22
  • [27] Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer
    Silagy, Andrew W.
    Woon, Dixon T. S.
    Kostos, Louise
    Bernardino, Rui
    Yiu, Ting W.
    Wettstein, Marian S.
    Goldberg, Hanan
    Herrera-Caceres, Jaime O.
    Shiakh, Hina
    Nason, Gregory
    Zlotta, Alexandre
    Diamantis, Eleftherios
    Bolton, Damien
    Fleshner, Neil
    BJU INTERNATIONAL, 2025,
  • [28] Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer
    Karzai, Fatima H.
    Madan, Ravi A.
    Figg, William D.
    SOUTHERN MEDICAL JOURNAL, 2015, 108 (04) : 224 - 228
  • [29] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [30] Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
    Leibowitz-Amit, R.
    Templeton, A. J.
    Omlin, A.
    Pezaro, C.
    Atenafu, E. G.
    Keizman, D.
    Vera-Badillo, F.
    Seah, J. -A.
    Attard, G.
    Knox, J. J.
    Sridhar, S. S.
    Tannock, I. F.
    de Bono, J. S.
    Joshua, A. M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 657 - 662
12345